Twin Peaks Wealth Advisors’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$33	–	1220
2025 Q2	$33	Buy	+1	New	+$25	﹤0.01%	2217

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Twin Peaks Wealth Advisors's KNSA Position: Q3 2025 in Review

Twin Peaks Wealth Advisors sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 1 share — an estimated $33 sold.

Twin Peaks Wealth Advisors first reported a position in KNSA in Q2 2025 and held it in 1 quarter. The position peaked at $33 in Q2 2025. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

Twin Peaks Wealth Advisors reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Twin Peaks Wealth Advisors sold 1 Kiniksa Pharmaceuticals share in Q3 2025, an estimated $33.
Twin Peaks Wealth Advisors first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Twin Peaks Wealth Advisors's Kiniksa Pharmaceuticals position peaked at $33 in Q2 2025.
204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Twin Peaks Wealth Advisors's 13F filing for Q3 2025, filed 30 Oct 2025.